Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Endometriosis is an abnormal, estrogen-dependent growth of endometrial tissue outside the uterus that frequently results in dysmenorrhea and pelvic pain and often causes infertility. Endometriosis is a significant burden on the quality of life of women. This study will assess the tolerability and how effective elagolix is in changing the disease symptoms in adult female participants with endometriosis.
Elagolix is an approved drug for treatment of endometriosis. Adult female participants with a diagnosis of endometriosis, who are prescribed elagolix by their physicians, in accordance with local clinical practice and label will be observed for up to 24 months. Around 80 female participants will be enrolled in the study in Israel.
Participants will receive Elagolix as prescribed by their physicians.
There may be a higher burden for participants in this study compared to standard of care. Patients report outcomes, in the form of questionnaires will be collected up to 24 months prospectively to assess the impact of elagolix on quality of life.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants Treated With Elagolix | Participants will receive Elagolix according to the local label. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Change in Dysmenorrhea (DYS), According to Patient Reported 11-Point Numeric Rating Scale (NRS) | Participants rated the change in DYS using an NRS. | Baseline (Month 0) to Month 3 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Dysmenorrhea (DYS), According to Patient Reported NRS | Participants rated the change in DYS using an NRS. | Baseline (Month 0) through Month 24 |
| Change in Non-Menstrual Pelvic Pain (NMPP), According to Patient Reported NRS |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult Female Participants diagnosed with endometriosis and experiencing Dysmenorrhea (DYS).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Meir Medical Center /ID# 224766 | Kfar Saba | Central District | 4428164 | Israel | ||
| Kaplan Medical Center /ID# 224773 |
Not provided
| Label | URL |
|---|---|
| Related info | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants rated the change in NMPP using an NRS.
| Baseline (Month 0) through Month 24 |
| Change in Dyspareunia, According to Patient Reported NRS | Participants rated the change in Dyspareunia using an NRS. | Baseline (Month 0) through Month 24 |
| Change in Level of Endometriosis Pain-through Patient Global Impression of Change (PGIC) | Participants will evaluate the change in their endometriosis-related pain since initiation of study drug, using the Patient Global Impression of Change (PGIC) questionnaire. | Baseline (Month 0) through Month 24 |
| Change in Quality of Life (QoL) through Endometriosis Health Profile-30 (EHP-30) | The EHP-30 is a disease-specific self-administered questionnaire used to measure health related QoL in women with endometriosis. | Baseline (Month 0) through Month 24 |
| Change in Treatment Satisfaction Though PGIC | Participants will evaluate the change in treatment satisfaction through PGIC questionnaire. | Baseline (Month 0) through Month 24 |
| Change in Treatment Satisfaction Though Clinician Global Impression of Change (CGIC) | The CGIC scale requiring the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention. | Baseline (Month 0) through Month 24 |
| Change in Work Productivity- through Work Productivity and Activity Impairment Questionnaire | The Work Productivity and Activity Impairment Questionnaire is used to measure the effect of general health and symptom severity on work productivity and regular activities during the past seven days. | Baseline (Month 0) through Month 24 |
| Change in Healthcare Resource Utilization Questionnaire (HCRU) Associated with Endometriosis Through HCRU Questionnaire | The HCRU will record the use of health resources (emergency room, physician visit, hospitalization, etc.) prior to and during the study. | Baseline (Month 0) through Month 24 |
| Evaluation of Elagolix Dosing | Elagolix dosing will be summarized by clinical diagnosis using descriptive statistics including mean, standard deviation, median, quartiles, minimum and maximum and 95% Confidence Interval (CI) for the mean. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Who Change Dose of Elagolix | Percentage of participants who change dose of elagolix. | Baseline (Month 0) through Month 24 |
| Reason Participants Change Dose of Elagolix | Reason participants change dose of elagolix. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Using Other Treatments of Endometriosis | Percentage of participants using other medications or procedures for the treatment of endometriosis. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Using Pain/Rescue Medications | Percentage of participants using pain/rescue medications. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Using Physiotherapy/Cognitive-Behavioral Therapy (Physio/CBT) During and Before the Course of this Observation Period | Percentage of participants using physio/CBT during and before the course of this observation period. | Baseline (Month 0) through Month 24 |
| Reason for Change at Subsequent Visits in Physiotherapy/Cognitive-Behavioral Therapy (Physio/CBT) During and Before the Course of this Observation Period | Reason for change at subsequent visits in physio/CBT during and before the course of this observation period. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Using Surgical Intervention During and Before the Course of this Observation Period | Percentage of participants using surgical intervention during and before the course of this observation period. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Using Add Back | Percentage of participants using add back. | Baseline (Month 0) through Month 24 |
| Percentage of Participants Using Concomitant Medications | Percentage of participants using concomitant medications. | Baseline (Month 0) through Month 24 |
| Number of Adverse Events (AEs) | An adverse event (AE) is defined as any untoward medical occurrence in a participant, which does not necessarily have a causal relationship with their treatment. | Baseline (Month 0) through Month 24 |
| Rehovot |
| Central District |
| 7660101 |
| Israel |
| Yitzhak Shamir Medical Center /ID# 224768 | Ẕerifin | Central District | 70300 | Israel |
| Hadassah Medical Center-Hebrew University /ID# 224769 | Jerusalem | Jerusalem | 91120 | Israel |
| Assuta Ashdod Medical Center /ID# 244898 | Ashdod | Southern District | 7747629 | Israel |
| Soroka University Medical Center /ID# 224774 | Beersheba | Southern District | 8410101 | Israel |
| The Chaim Sheba Medical Center /ID# 224764 | Ramat Gan | Tel Aviv | 5265601 | Israel |
| Tel Aviv Sourasky Medical Center /ID# 224765 | Tel Aviv | Tel Aviv | 6423906 | Israel |
| Maccabi Health Services /ID# 224775 | Tel Aviv | Tel Aviv | 6789140 | Israel |
| Clalit Health Services /ID# 224771 | Haifa | 3515210 | Israel |
| ID | Term |
|---|---|
| D004715 | Endometriosis |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
Not provided
Not provided